Drug news
Nivolumab is approved in Japan for unresectable Melanoma- Ono/BMS
ONO Pharma has received manufacturing and marketing approval for the human anti-human PD-1 monoclonal antibody Opdivo Intravenous Infusion 20 mg/100 mg (nivolumab) for the treatment of unresectable Melanoma.
Ono Pharma is the first company in the world to get an approval for a PD-1 checkpoint inhibitor which it holds under licence for Japan, South Korea and Taiwan from BMS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins